Please login to the form below
Aximris
This page shows the latest Aximris news and features for those working in and with pharma, biotech and healthcare.
FDA committee rejects Intellipharmaceutics’ opioid drug Aximris
The FDA committee panel voted 24 to 2 against the approval of Aximris in this indication. ... sale of Aximris in the US market, or that it will ever be successfully commercialised”.
Latest news
More from news
Approximately 1 fully matching, plus 0 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- Medical Writers > Scientific Directors – Medical Communicatio...
-
Highly Competitive Salary, Bonus &Benefits
- AM / Senior Account Manager – Healthcare PR - London / Remote
-
Highly Competitive Salary, Bonus &Benefits
- FREELANCE Associate Director - Healthcare PR - Remote or London
-
Superb Day Rate &Benefits
- Vaccines writer – career opportunity to move into medcomms from ...
-
Highly competitive salary
- Senior Account Exec > CSD – Medical Communications – UK, Lond...
-
Highly Competitive Salary, Bonus &Benefits
- Client Services Director, MRNA/ Covid 19, Medical Communications...
-
Highly competitive salary
- Principal Medical Writer, MRNA/ Covid 19, Medical Communications...
-
Highly competitive salary
- Scientific Director, MRNA/ Covid 19, Medical Communications, UK
-
Six figure salary
-
B2B media account director
-
Competitive salary
- MHRA approves second COVID-19 antibody treatment
- Sanofi to buy acne specialist Origimm
- Roche acquires test maker TIB Molbiol
- Merck enters agreement with Hanmi for investigational NASH drug
- AstraZeneca blocks take-private buyout of Sobi
- Merck, Eisai’s Keytruda/Lenvima regimen scores full approval in endometrial cancer
No results were found
PMHub
IGNIFI
We’re IGNIFI. An independent creative agency, we help spark and sustain successful brands for some of the biggest names in...
Latest intelligence
- Diversity in clinical trials: looking back at our 2021 blogs
- In this blog, we look back at the Innovative Trials' Equality & Diversity (E&D) committee blogs across 2021...
- What does the future hold for Light-chain Amyloidosis?
- Recent advances in the understanding and treatment are reforming pharma’s approach to the management of this rare disease. With a new standard of care rapidly developing, what does the landscape...
- Webinar:
- Securing a future for telehealth with immersive market research insights...
